GlobeNewswire·Feb 20, 2026, 8:30 AM ET

CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference

CytoDyn Inc. presented new preclinical, translational, and clinical data on leronlimab at the AACR Immuno-Oncology Conference in Los Angeles on February 18-21, 2026.
Leronlimab is a first-in-class monoclonal antibody targeting the CCR5 receptor being evaluated for metastatic triple-negative breast cancer (mTNBC) and colorectal cancer.
Mechanistic findings indicate leronlimab modulates T-cell exhaustion pathways & increases PD-L1/PD-1 expression to potentially enhance immune checkpoint inhibitor (ICI) responses.
In Rhesus monkeys, leronlimab induced PD-1 expression in T cells.
The drug significantly reduced immunosuppressive mediators (sB7-H3, BAFF, & sTyro3) secreted by TNBC cells following CCR5 blockade.
A pooled retrospective analysis of 28 heavily pretreated mTNBC patients showed a favorable safety profile with no therapy-limiting toxicities.
Five of the 28 patients (17.9%) remained alive after a median follow-up exceeding 63 months.
Data presented by Associate Professor Xuanmao Jiao suggests CCR5 inhibition aligns mechanistic insights with long-term survival observations in mTNBC.